| 1 |
He C, Chen L, Yang J, Chen Z, Lei H, Hong W, Song X, Yang L, Li J, Wang W, Shen G, Lu G, Wei X. Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants. Mol Biomed 2023;4:9. [PMID: 36894743 DOI: 10.1186/s43556-023-00121-7] [Reference Citation Analysis]
|
| 2 |
Mohapatra RK, Verma S, Kandi V, Sarangi AK, Seidel V, Das SN, Behera A, Tuli HS, Sharma AK, Dhama K. The SARS‐CoV‐2 Omicron Variant and its Multiple Sub‐lineages: Transmissibility, Vaccine Development, Antiviral Drugs, Monoclonal Antibodies, and Strategies for Infection Control – a Review. ChemistrySelect 2023;8. [DOI: 10.1002/slct.202201380] [Reference Citation Analysis]
|
| 3 |
Lu C, Zhang Y, Liu X, Hou F, Cai R, Yu Z, Liu F, Yang G, Ding J, Xu J, Hua X, Cheng X, Pan X, Liu L, Lin K, Wang Z, Li X, Lu J, Zhang Q, Li Y, Hu C, Fan H, Liu X, Wang H, Jia R, Xu F, Wang X, Huang H, Zhao R, Li J, Cheng H, Jia W, Yang X. Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine. Antiviral Res 2023;212:105556. [PMID: 36871919 DOI: 10.1016/j.antiviral.2023.105556] [Reference Citation Analysis]
|
| 4 |
Felbinger N, Trudil D, Loomis L, Ascione R, Siragusa G, Haba S, Rastogi S, Mucci A, Claycomb M, Snowberger S, Luke B, Francesconi S, Tsang S. Epitope mapping of SARS-CoV-2 spike protein differentiates the antibody binding activity in vaccinated and infected individuals. Front Virol 2023;3. [DOI: 10.3389/fviro.2023.988109] [Reference Citation Analysis]
|
| 5 |
Negar Firouzabadi, Parisa Ghasemiyeh, Fatemeh Moradishooli, Soliman Mohammadi-Samani. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. Int Immunopharmacol 2023:109968. [ DOI: 10.1016/j.intimp.2023.109968] [Reference Citation Analysis]
|
| 6 |
Lanyon HE, Hoyle JS, Downard KM. Resolving omicron sub-variants of SARS CoV-2 coronavirus with MALDI mass spectrometry. Analyst 2023;148:966-72. [PMID: 36757162 DOI: 10.1039/d2an01843h] [Reference Citation Analysis]
|
| 7 |
Shen F, Yang CX, Lu Y, Zhang M, Tian RR, Dong XQ, Li AQ, Zheng YT, Pang W. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines. J Med Virol 2023;95:e28516. [PMID: 36680413 DOI: 10.1002/jmv.28516] [Reference Citation Analysis]
|
| 8 |
AlKalamouni H, Abou Hassan FF, Bou Hamdan M, Page AJ, Lott M, Matthews M, Ghosn N, Rady A, Mahfouz R, Araj GF, Dbaibo G, Zaraket H, Melhem NM, Matar GM. Genomic surveillance of SARS-CoV-2 in COVID-19 vaccinated healthcare workers in Lebanon. BMC Med Genomics 2023;16:14. [PMID: 36707851 DOI: 10.1186/s12920-023-01443-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Kuzel TG, Fu J, Anderson M, Stec M, Boler M, Behun D, Gosha A, Cloherty G, Landay A, Moy J. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals. Vaccine 2023;41:879-82. [PMID: 36572601 DOI: 10.1016/j.vaccine.2022.12.049] [Reference Citation Analysis]
|
| 10 |
Chen J, Yang J, Chang F, Hu Y, Wu Q, Teng S, Liu Y, Zhang J, He R, Liu B, Zheng X, Liu Z, Peng Y, Xie Z, Zhang Y, Lu R, Pan D, Wang Y, Peng L, Liu W, Li YP, Qu X. Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients. Virol Sin 2023:S1995-820X(23)00005-6. [PMID: 36682433 DOI: 10.1016/j.virs.2023.01.005] [Reference Citation Analysis]
|
| 11 |
Liu Y, Peng H, Xiang T, Xu F, Jiang Y, Zhong L, Peng Y, Le A, Zhang W. Redistribution and activation of CD16brightCD56dimNK cell subset to fight against Omicron subvariant BA.2 after COVID-19 vaccination.. [DOI: 10.1101/2023.01.13.524025] [Reference Citation Analysis]
|
| 12 |
Stati G, Amerio P, Nubile M, Sancilio S, Rossi F, Di Pietro R. Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery. Int J Mol Sci 2023;24. [PMID: 36674919 DOI: 10.3390/ijms24021404] [Reference Citation Analysis]
|
| 13 |
Chen DY, Kenney D, Chin CV, Tavares AH, Khan N, Conway HL, Liu G, Choudhary MC, Gertje HP, O'Connell AK, Kotton DN, Herrmann A, Ensser A, Connor JH, Bosmann M, Li JZ, Gack MU, Baker SC, Kirchdoerfer RN, Kataria Y, Crossland NA, Douam F, Saeed M. Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron. bioRxiv 2023:2022. [PMID: 36263066 DOI: 10.1101/2022.10.13.512134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 14 |
Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses 2023;15. [PMID: 36680207 DOI: 10.3390/v15010167] [Reference Citation Analysis]
|
| 15 |
Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, Zhou H, Islam MR, Mamada SS, Kusuma HI, Rabaan AA, Alhumaid S, Mutair AA, Iqhrammullah M, Al-Tawfiq JA, Mohaini MA, Alsalman AJ, Tuli HS, Chakraborty C, Harapan H. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health 2023;16:4-14. [PMID: 36446204 DOI: 10.1016/j.jiph.2022.11.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 16 |
Singh JK, Dubey S, Srivastava G, Siddiqi MI, Srivastava SK. Neohesperidin and spike RBD interaction in omicron and its sub-variants: In silico, structural and simulation studies. Comput Biol Med 2023;152:106392. [PMID: 36502697 DOI: 10.1016/j.compbiomed.2022.106392] [Reference Citation Analysis]
|
| 17 |
Dong Y, Li X, Li Z, Zhu Y, Wei Z, He J, Cheng H, Yang A, Chen F. Effects of inactivated SARS-CoV-2 vaccination on male fertility: A retrospective cohort study. J Med Virol 2023;95:e28329. [PMID: 36415120 DOI: 10.1002/jmv.28329] [Reference Citation Analysis]
|
| 18 |
Wang R, Huang H, Yu C, Sun C, Ma J, Kong D, Lin Y, Zhao D, Zhou S, Lu J, Cao S, Zhang Y, Luo C, Li X, Wang Y, Xie L. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants. Sci China Life Sci 2022;:1-13. [PMID: 36598621 DOI: 10.1007/s11427-022-2207-7] [Reference Citation Analysis]
|
| 19 |
Ramadan Abdelmoez Farahat, Abdelaziz Abdelaal, Tungki Pratama Umar, Amro A. El-Sakka, Amira Yasmine Benmelouka, Khaled Albakri, Iftikhar Ali, Tareq Al-Ahdal, Basel Abdelazeem, Ranjit Sah, Alfonso J. Rodriguez-Morales. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends. Infez Med 2022;30. [PMID: 36482957 DOI: 10.53854/liim-3004-2] [Reference Citation Analysis]
|
| 20 |
Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Xiang T, Wang J, Zheng X. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. Virol Sin 2022:S1995-820X(22)00191-2. [PMID: 36427646 DOI: 10.1016/j.virs.2022.11.007] [Reference Citation Analysis]
|
| 22 |
Mahilkar S, Agrawal S, Chaudhary S, Parikh S, Sonkar SC, Verma DK, Chitalia V, Mehta D, Koner BC, Vijay N, Shastri J, Sunil S. SARS-CoV-2 variants: Impact on biological and clinical outcome. Front Med 2022;9. [DOI: 10.3389/fmed.2022.995960] [Reference Citation Analysis]
|
| 23 |
Kamran Zaman, Anita M. Shete, Shailendra Kumar Mishra, Abhinendra Kumar, Mahendra M. Reddy, Rima R. Sahay, Shailendra Yadav, Triparna Majumdar, Ashok K. Pandey, Gaurav Raj Dwivedi, Hirawati Deval, Rajeev Singh, Sthita Pragnya Behera, Niraj Kumar, Savita Patil, Ashish Kumar, Manisha Dudhmal, Yash Joshi, Aishwarya Shukla, Pranita Gawande, Asif Kavathekar, Nalin Kumar, Vijay Kumar, Kamlesh Kumar, Ravi Shankar Singh, Manoj Kumar, Shashikant Tiwari, Ajay Verma, Pragya D. Yadav, Rajni Kant. Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India. Front Med (Lausanne) 2022;9:955930. [PMID: 36405589 DOI: 10.3389/fmed.2022.955930] [Reference Citation Analysis]
|
| 24 |
Park YJ, Pinto D, Walls AC, Liu Z, De Marco A, Benigni F, Zatta F, Silacci-Fregni C, Bassi J, Sprouse KR, Addetia A, Bowen JE, Stewart C, Giurdanella M, Saliba C, Guarino B, Schmid MA, Franko NM, Logue JK, Dang HV, Hauser K, di Iulio J, Rivera W, Schnell G, Rajesh A, Zhou J, Farhat N, Kaiser H, Montiel-Ruiz M, Noack J, Lempp FA, Janer J, Abdelnabi R, Maes P, Ferrari P, Ceschi A, Giannini O, de Melo GD, Kergoat L, Bourhy H, Neyts J, Soriaga L, Purcell LA, Snell G, Whelan SPJ, Lanzavecchia A, Virgin HW, Piccoli L, Chu HY, Pizzuto MS, Corti D, Veesler D. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 2022;:eadc9127. [PMID: 36264829 DOI: 10.1126/science.adc9127] [Reference Citation Analysis]
|
| 25 |
Rahman S, Hossain MJ, Nahar Z, Shahriar M, Bhuiyan MA, Islam MR. Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic. Environ Health Insights 2022;16:11786302221129396. [PMID: 36299441 DOI: 10.1177/11786302221129396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Tulimilli SV, Dallavalasa S, Basavaraju CG, Kumar Rao V, Chikkahonnaiah P, Madhunapantula SV, Veeranna RP. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines (Basel) 2022;10. [PMID: 36298616 DOI: 10.3390/vaccines10101751] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Błaszczuk A, Michalski A, Sikora D, Malm M, Drop B, Polz-Dacewicz M. Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant. Vaccines (Basel) 2022;10:1728. [PMID: 36298593 DOI: 10.3390/vaccines10101728] [Reference Citation Analysis]
|
| 28 |
Valério M, Borges-Araújo L, Melo MN, Lousa D, Soares CM. SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. Front Med Technol 2022;4:1009451. [PMID: 36277437 DOI: 10.3389/fmedt.2022.1009451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Chavda VP, Yao Q, Vora LK, Apostolopoulos V, Patel CA, Bezbaruah R, Patel AB, Chen Z. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Front Immunol 2022;13:961198. [DOI: 10.3389/fimmu.2022.961198] [Reference Citation Analysis]
|
| 30 |
Sobczak M, Pawliczak R. Factors That Affect the COVID-19 Pandemic in Summer 2022 Compared to Summer 2021. Int J Environ Res Public Health 2022;19. [PMID: 36231856 DOI: 10.3390/ijerph191912561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Shaheen N, Mohamed A, Attalla A, Diab RA, Swed S, Nashwan AJ, Rababah AA, Hefnawy MT, Soliman Y, Abdelwahab OA, Desouki MT, Khaity A, Shaheen A, Ramadan A, Meshref M. Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review. IDR 2022;Volume 15:6317-6330. [DOI: 10.2147/idr.s387551] [Reference Citation Analysis]
|
| 32 |
Lueking R, Clark AE, Narasimhan M, Mahimainathan L, Muthukumar A, Larsen CP, Sorelle JA. SARS-CoV-2 coinfections with variant genomic lineages identified by multiplex fragment analysis. Front Genet 2022;13:942713. [DOI: 10.3389/fgene.2022.942713] [Reference Citation Analysis]
|
| 33 |
Le TTB, Vasanthakumaran T, Thi Hien HN, Hung IC, Luu MN, Khan ZA, An NT, Tran VP, Lee WJ, Abdul Aziz JM, Ali T, Dumre SP, Huy NT. SARS-CoV-2 Omicron and its current known unknowns: A narrative review. Rev Med Virol 2023;33:e2398. [PMID: 36150052 DOI: 10.1002/rmv.2398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Wang R, Huang X, Cao T, Sun C, Luo D, Qiu H, Wu M, Huang X, Yu C, Li J, Kong D, Ma J, Zhang X, Hu P, Zhang Y, Luo C, Zhao H, Li Y, Deng Y, Qin C, Xie L. Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants. Virology 2022;576:61-8. [PMID: 36174448 DOI: 10.1016/j.virol.2022.09.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 35 |
Rana R, Kant R, Huirem RS, Bohra D, Ganguly NK. Omicron variant: Current insights and future directions. Microbiol Res 2022;265:127204. [PMID: 36152612 DOI: 10.1016/j.micres.2022.127204] [Reference Citation Analysis]
|
| 36 |
Berno G, Fabeni L, Matusali G, Gruber CEM, Rueca M, Giombini E, Garbuglia AR. SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods. Pathogens 2022;11:1058. [PMID: 36145490 DOI: 10.3390/pathogens11091058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 37 |
Lu C, Zhang Y, Liu X, Hou F, Cai R, Yu Z, Liu F, Yang G, Ding J, Xu J, Hua X, Pan X, Liu L, Lin K, Wang Z, Li X, Lu J, Zhang Q, Li Y, Hu C, Fan H, Liu X, Wang H, Jia R, Xu F, Wang X, Huang H, Zhao R, Li J, Cheng H, Jia W, Yang X. Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.. [DOI: 10.1101/2022.09.06.506714] [Reference Citation Analysis]
|
| 38 |
Barozi V, Edkins AL, Tastan Bishop Ö. Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: Allosteric communications between and within viral and human proteins. Comput Struct Biotechnol J 2022;20:4562-78. [PMID: 35989699 DOI: 10.1016/j.csbj.2022.08.015] [Reference Citation Analysis]
|
| 39 |
Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 40 |
Smither SJ, Kempster S, Priestnall SL, Suárez-Bonnet A, Stapleton H, Laws TR, Ferguson D, Almond N, Lever MS, Williamson ED. Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19. Viruses 2022;14. [PMID: 36016391 DOI: 10.3390/v14081769] [Reference Citation Analysis]
|
| 41 |
Barozi V, Edkins AL, Bishop ÖT. Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: allosteric communications between and within viral and human proteins.. [DOI: 10.1101/2022.08.06.503019] [Reference Citation Analysis]
|
| 42 |
Singh P, Negi SS, Bhargava A, Kolla VP, Arora RD. Preliminary Genomic Analysis of the Omicron Variants of SARS-CoV-2 in Central India During the third wave of the COVID-19 Pandemic. Archives of Medical Research 2022. [DOI: 10.1016/j.arcmed.2022.08.006] [Reference Citation Analysis]
|
| 43 |
Peronace C, Tallerico R, Colosimo M, Fazio MD, Pasceri F, Talotta I, Panduri G, Pintomalli L, Oteri R, Calantoni V, Fiorillo MT, Caroleo MC, Curcio R, Dolce V, Cione E, Minchella P. The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants. Biomedicines 2022;10:1839. [DOI: 10.3390/biomedicines10081839] [Reference Citation Analysis]
|
| 44 |
Hertanto DM, Sutanto H, Lusida MI, Kuntaman K, Santoso D. The genomic and clinical features of the COVID-19 Omicron variant: a narrative review. F1000Res 2022;11:353. [DOI: 10.12688/f1000research.110647.2] [Reference Citation Analysis]
|
| 45 |
Aoki A, Adachi H, Mori Y, Ito M, Sato K, Okuda K, Sakakibara T, Okamoto Y, Jinno H. Discrimination of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 Using a High-Resolution Melting-Based Assay: a Pilot Study. Microbiol Spectr 2022;:e0136722. [PMID: 35861527 DOI: 10.1128/spectrum.01367-22] [Reference Citation Analysis]
|
| 46 |
Grikscheit K, Rabenau HF, Ghodratian Z, Widera M, Wilhelm A, Toptan Grabmair T, Hoehl S, Layer E, Helfritz F, Ciesek S. Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination. Vaccines 2022;10:1163. [DOI: 10.3390/vaccines10071163] [Reference Citation Analysis]
|
| 47 |
Li Y, Shen Y, Zhang Y, Yan R. Structural basis for the enhanced infectivity and immune evasion of Omicron subvariants.. [DOI: 10.1101/2022.07.13.499586] [Reference Citation Analysis]
|
| 48 |
Giron CC, Laaksonen A, Barroso da Silva FL. Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2095305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Maeda R, Fujita J, Konishi Y, Kazuma Y, Yamazaki H, Anzai I, Watanabe T, Yamaguchi K, Kasai K, Nagata K, Yamaoka Y, Miyakawa K, Ryo A, Shirakawa K, Sato K, Makino F, Matsuura Y, Inoue T, Imura A, Namba K, Takaori-kondo A. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. Commun Biol 2022;5. [DOI: 10.1038/s42003-022-03630-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Ghazvini K, Keikha M. What we recognize about omicron sub-lineage BA.2 as a global new challenge? - Correspondence. Int J Surg 2022;103:106704. [PMID: 35697323 DOI: 10.1016/j.ijsu.2022.106704] [Reference Citation Analysis]
|
| 51 |
Tarcsai KR, Corolciuc O, Tordai A, Ongrádi J. SARS-CoV-2 infection in HIV-infected patients: potential role in the high mutational load of the Omicron variant emerging in South Africa. Geroscience 2022;44:2337-45. [PMID: 35739343 DOI: 10.1007/s11357-022-00603-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 52 |
Bazargan M, Elahi R, Esmaeilzadeh A. OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. J Gene Med 2022;:e3435. [PMID: 35726542 DOI: 10.1002/jgm.3435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 53 |
Dutta D, Naiyer S, Mansuri S, Soni N, Singh V, Bhat KH, Singh N, Arora G, Mansuri MS. COVID-19 Diagnosis: A Comprehensive Review of the RT-qPCR Method for Detection of SARS-CoV-2. Diagnostics 2022;12:1503. [DOI: 10.3390/diagnostics12061503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 54 |
Kumar S, Karuppanan K, Subramaniam G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. J Med Virol 2022. [PMID: 35680610 DOI: 10.1002/jmv.27927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 55 |
Hoteit R, Yassine HM. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. Vaccines (Basel) 2022;10:919. [PMID: 35746526 DOI: 10.3390/vaccines10060919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 56 |
Al Kalamouni H, Abou Hassan FF, Bou Hamdan M, Page AJ, Lott M, Ghosn N, Rady A, Mahfouz R, Araj GF, Dbaibo G, Zaraket H, Melhem NM, Matar GM. Genomic Surveillance of SARS CoV2 in COVID-19 vaccinated healthcare workers in Lebanon.. [DOI: 10.1101/2022.06.06.494965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Zhou H, Møhlenberg M, Thakor JC, Tuli HS, Wang P, Assaraf YG, Dhama K, Jiang S. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Clin Microbiol Rev. [DOI: 10.1128/cmr.00014-22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 58 |
Khandia R, Singhal S, Alqahtani T, Kamal MA, El-Shall NA, Nainu F, Desingu PA, Dhama K. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res 2022;209:112816. [PMID: 35093310 DOI: 10.1016/j.envres.2022.112816] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 107.0] [Reference Citation Analysis]
|
| 59 |
López-cortés GI, Palacios-pérez M, Veledíaz HF, Hernández-aguilar M, López-hernández GR, Zamudio GS, José MV. The Spike Protein of SARS-CoV-2 Is Adapting Because of Selective Pressures. Vaccines 2022;10:864. [DOI: 10.3390/vaccines10060864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 60 |
Sanyaolu A, Marinkovic A, Prakash S, Haider N, Williams M, Okorie C, Badaru O, Smith S. SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape. World J Virol 2022; 11(3): 137-143 [DOI: 10.5501/wjv.v11.i3.137] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 61 |
Celik I, Abdellattif MH, Tallei TE. An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2. Biology (Basel) 2022;11:797. [PMID: 35625526 DOI: 10.3390/biology11050797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 62 |
Xue L, Jing S, Zhang K, Milne R, Wang H. Infectivity versus fatality of SARS-CoV-2 mutations and influenza. Int J Infect Dis 2022;121:195-202. [PMID: 35584743 DOI: 10.1016/j.ijid.2022.05.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 63 |
Cheng SM, Mok CKP, Chan KC, Ng SS, Lam BH, Luk LL, Ko FW, Chen C, Yiu K, Li JK, Chan KK, Tsang LC, Poon LL, Hui DS, Peiris M. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Euro Surveill 2022;27. [PMID: 35514306 DOI: 10.2807/1560-7917.ES.2022.27.18.2200178] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 64 |
Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant. J Phys Chem Lett 2022;:3840-9. [PMID: 35467344 DOI: 10.1021/acs.jpclett.2c00469] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 65 |
Felbinger N, Trudil D, Loomis L, Ascione R, Siragusa G, Haba S, Rastogi S, Mucci A, Claycomb M, Snowberger S, Luke B, Francesconi S, Tsang S. Epitope Mapping of SARS-CoV-2 Spike Protein Reveals Distinct Antibody Binding Activity of Vaccinated and Infected Individuals.. [DOI: 10.1101/2022.04.13.487697] [Reference Citation Analysis]
|
| 66 |
Aoki A, Adachi H, Mori Y, Ito M, Sato K, Okuda K, Sakakibara T, Okamoto Y, Jinno H. Discrimination of SARS-CoV-2 Omicron sub-lineages BA.1 and BA.2 using a high-resolution melting-based assay: A pilot study.. [DOI: 10.1101/2022.04.11.487970] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 67 |
Li Q, Zhang M, Liang Z, Zhang L, Wu X, Yang C, An Y, Tong J, Liu S, Li T, Cui Q, Nie J, Wu J, Huang W, Wang Y. Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD. MedComm 2022;3. [DOI: 10.1002/mco2.130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 68 |
Zhang J, Ejikemeuwa A, Gerzanich V, Nasr M, Tang Q, Simard JM, Zhao RY. Understanding the Role of SARS-CoV-2 ORF3a in Viral Pathogenesis and COVID-19. Front Microbiol 2022;13:854567. [PMID: 35356515 DOI: 10.3389/fmicb.2022.854567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 69 |
Abas AH, Marfuah S, Idroes R, Kusumawaty D, Fatimawali, Park MN, Siyadatpanah A, Alhumaydhi FA, Mahmud S, Tallei TE, Emran TB, Kim B. Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19? Molecules 2022;27:2221. [DOI: 10.3390/molecules27072221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 70 |
Berkhout B, Herrera-Carrillo E. SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant. J Virol 2022;:e0009022. [PMID: 35293771 DOI: 10.1128/jvi.00090-22] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 71 |
Lippi G, Henry BM, Adeli K, Plebani M. Fujirebio Lumipulse SARS-CoV-2 antigen immunoassay: pooled analysis of diagnostic accuracy. Diagnosis (Berl) 2022. [PMID: 35287253 DOI: 10.1515/dx-2022-0021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 72 |
Dhawan M, Priyanka, Choudhary OP. Emergence of Omicron sub-variant BA.2: Is it a matter of concern amid the COVID-19 pandemic? Int J Surg 2022;99:106581. [PMID: 35202859 DOI: 10.1016/j.ijsu.2022.106581] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 73 |
Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. Res Sq 2022:rs. [PMID: 35233567 DOI: 10.21203/rs.3.rs-1362445/v1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 74 |
Mahase E. Covid-19: What do we know about omicron sublineages? BMJ 2022;376:o358. [PMID: 35149516 DOI: 10.1136/bmj.o358] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 75 |
Kumar S, Karuppanan K, Subramaniam G. Omicron (BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment.. [DOI: 10.1101/2022.02.11.480029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 76 |
Colson P, Delerce J, Beye M, Levasseur A, Boschi C, Houhamdi L, Tissot-dupont H, Yahi N, Million M, La Scola B, Fantini J, Raoult D, Fournier P. First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.. [DOI: 10.1101/2022.02.08.22270495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 77 |
Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. ArXiv 2022:arXiv. [PMID: 35169598] [Reference Citation Analysis]
|
| 78 |
Singh J, Panwar A, Anantharaj A, Rani C, Bhardwaj M, Kumar P, Pargai K, Chattopadhyay P, Devi P, Maurya R, Mishra P, Pandey AK, Pandey R, Medigeshi GR. BA.1 and BA.2 sub-lineages of Omicron variant have comparable replication kinetics and susceptibility to neutralization by antibodies.. [DOI: 10.1101/2022.01.28.22269990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 79 |
Mingaleeva RN, Nigmatulina NA, Sharafetdinova LM, Romozanova AM, Gabdoulkhakova AG, Filina YV, Shavaliyev RF, Rizvanov AA, Miftakhova RR. Biology of the SARS-CoV-2 Coronavirus. Biochemistry (Mosc) 2022;87:1662-78. [PMID: 36717455 DOI: 10.1134/S0006297922120215] [Reference Citation Analysis]
|
| 80 |
Das S, Samanta S, Banerjee J, Pal A, Giri B, Kar SS, Dash SK. Is Omicron the end of pandemic or start of a new innings? Travel Med Infect Dis 2022;48:102332. [PMID: 35472451 DOI: 10.1016/j.tmaid.2022.102332] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
|
